Zevra Therapeutics price target raised to $21 from $20 at Guggenheim

Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $21 from $20 and keeps a Buy rating on the shares. The firm, which is refreshing its model ahead of end-of-FY24 earnings, expects to get an early look at the launch metrics and sales for the recently approved Miplyffa for Niemann-Pick Disease Type C. In Q4, the firm models $5M for U.S. Miplyffa sales.